WFG Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

WFG Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$0	Buy	104 +18	+21%	+$41	﹤0.01%	1754
2017 Q1	$0	Sell	86 -18	-17%	-$40	﹤0.01%	1768
2016 Q4	$0	Sell	104 -550	-84%	-$1.53K	﹤0.01%	1853
2016 Q3	$2K	Hold	654	–	–	﹤0.01%	1434
2016 Q2	$2K	Hold	654	–	–	﹤0.01%	1419
2016 Q1	$2K	Buy	654 +40	+7%	+$125	﹤0.01%	1381
2015 Q4	$2K	Buy	614 +64	+12%	+$268	﹤0.01%	1418
2015 Q3	$3K	Buy	+550	New	+$3.15K	﹤0.01%	1380
2015 Q2	–	Sell	-2,000	Closed	-$14K	–	1919
2015 Q1	$14K	Sell	2,000 -2,370	-54%	-$17.2K	﹤0.01%	1112
2014 Q4	$34K	Sell	4,370 -7,367	-63%	-$58.3K	0.01%	1044
2014 Q3	$88K	Buy	11,737 +71	+0.6%	+$659	0.02%	711
2014 Q2	$113K	Buy	11,666 +68	+0.6%	+$606	0.02%	618
2014 Q1	$96K	Buy	11,598 +660	+6%	+$5.66K	0.02%	651
2013 Q4	$92K	Sell	10,938 -16,320	-60%	-$138K	0.01%	778
2013 Q3	$217K	Buy	27,258 +12,782	+88%	+$103K	0.03%	462
2013 Q2	$112K	Buy	+14,476	New	+$113K	0.02%	626

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

WFG Advisors's PDLI Position: Q2 2017 in Review

WFG Advisors increased its PDL BioPharma, Inc. (PDLI) stake by 21% in Q2 2017, buying an estimated $41 and bringing the position to 104 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1754.

WFG Advisors first reported a position in PDLI in Q2 2013 and has held it in 16 quarters since. The position peaked at $217K in Q3 2013. 171 funds tracked by Wall St. Rank hold PDLI as of Q2 2017.

WFG Advisors held 104 shares of PDL BioPharma, Inc. worth $0 as of Q2 2017.
WFG Advisors bought 18 PDL BioPharma, Inc. shares in Q2 2017, an estimated $41.
PDL BioPharma, Inc. made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1754 holding.
WFG Advisors first reported a position in PDL BioPharma, Inc. in Q2 2013 and has held it in 16 quarters since.
WFG Advisors's PDL BioPharma, Inc. position peaked at $217K in Q3 2013.
171 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.